NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted with Cobicistat in Healthy Volunteers

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Institutes of Health Clinical Center (CC)

Recruitment Detail

Type: Completed Study; data analyses ongoing
Gender: Male & Female
Min Age: 18 Years
Max Age: 65 Years

Referral Letter Required


Population Exclusion(s)

Pregnant Women;


Fixed Sequence;
Intrasubject Drug-Drug Interaction;

Recruitment Keyword(s)



HIV Infected Population with Latent Tuberculosis

Investigational Drug(s)


Investigational Device(s)



Drug: rifapentene (RPT)
Drug: darunavir/cobicistat (DRV/c)
Drug: Isoniazid (INH)
Dietary Supplement: Pyridoxine

Supporting Site

NIH Clinical Center

People with human immunodeficiency virus (HIV) often take several medicines to control HIV. Dolutegravir and darunavir boosted with cobicistat are HIV medicines that people may take. They may also need to take medicines for an infection called latent tuberculosis (TB). Researchers think a once-weekly treatment for latent TB would be easier for people with HIV to take. This once weekly treatment consists of two drugs: rifapentine and isoniazid. However, they need to see how TB drugs and HIV drugs interact.


To learn how anti-HIV and anti-TB drugs affect each other so that people taking these drugs together can be treated safely.


Healthy adults ages 18 65.


Participants will be screened with a medical history and physical exam. They will have vital signs taken and give a blood sample. Women will have a pregnancy test.

Participants cannot take any other medicines during the study, including vitamins. Only occasional, infrequent use of acetaminophen (Tylenol , max 2000 mg/day), ibuprofen (Motrin or Advil ), naproxen (Aleve ), loperamide (Imodium ), and/or antihistamines (such as Benadryl , Zyrtec , Claritin , etc.) will be allowed.

Participants will be assigned to one of three groups. Each group will take a different study drug, once or twice a day, for 19 23 days. At the baseline study visit, they will get a supply of the study drug tablets and instructions for taking them. Participants will keep a medicine diary to serve as a memory aid for taking medicine and reporting any side effects that they may experience.

Participants will have 8 or 9 study visits over about 40 days. The number of visits depends on which group the person is assigned to. All visits will take place at the NIH Clinical Center. Participants will fast before study visits.

The baseline visit will last about 2 3 hours. There will be 3-4 long visits that will last for about 12 hours. The other 4-5 visits will last about 1 hour.

During all study visits, screening procedures will be repeated. During long visits, an intravenous (IV) line will be inserted into an arm vein with a needle. It will be used to take blood.

--Back to Top--



A subject will be considered eligible for this study only if all of the following criteria are met:

1. Ages 18 - 65 years

2. Weight greater than or equal to 45 kg and less than or equal to 120; BMI greater than or equal to 18.0 and <30

3. Judged to be healthy based on medical history, physical examination, vital signs, and clinical laboratory tests (liver function tests (AST, ALT, Tbili) greater than or equal to upper limit of normal [ULN], serum creatinine (SCr) less than or equal to ULN, CK less than or equal to 2X ULN, platelets (PLT) >150,0000/mm3, hemoglobin (Hgb) >11 g/dL), C-reactive protein (CRP) less than or equal to ULN)

4. Negative QuantiFERON-TB Gold test at screening

5. HIV-negative, as determined by standard serologic assays for HIV infection.

6. No laboratory evidence of active Hepatitis A, B, or C infection

7. Willing to abstain from alcohol consumption throughout the study period

8. Subject agrees to genetic testing and storage of specimens for future research

9. Negative serum or urine pregnancy test for females of child-bearing potential

10. For female subjects able to become pregnant (i.e., have not undergone surgical sterilization or are not postmenopausal), willingness to prevent pregnancy during the study period by:

a. Practicing absolute abstinence from sexual contact or

b. Committing to use of effective non-hormonal and/or barrier methods of birth control during any and all sexual encounters. Acceptable methods are as follows:

- Condom, diaphragm, or cervical cap with a spermicide

- Intrauterine device (IUD) without hormones

- Male partner with a vasectomy


A subject will be ineligible for this study if 1, or more, of the following criteria are met:

1. Known hypersensitivity to dolutegravir, darunavir, cobicistat, rifapentine and other rifamycin analogues, or isoniazid

2. History of type 1 hypersensitivity reaction to sulfonamides

3. History or presence of any of the following:

a. Latent or active TB infection

b. Gastrointestinal disease that is uncontrolled, requires daily treatment with medication, or would interfere with a subject s ability to absorb drugs (diarrhea, pancreatitis, peptic ulcer disease, etc.),

c. Renal impairment (chronic renal insufficiency of any CKD stage, or acute renal failure not induced by drug therapy defined as GFR < 90 ml/min)

d. Respiratory disease that is uncontrolled or requires daily treatment with medication (asthma, chronic obstructive pulmonary disease, etc.)

e. Cardiovascular disease (hypertension [systolic blood pressure >140 mmHg or diastolic blood pressure > 90 mmHg], heart failure, arrhythmia, etc.)

f. Metabolic disorders (diabetes mellitus, etc.)

g. Hematologic or bleeding disorders (anemia, hemophilia, serious/major bleeding events, menorrhagia (female subjects), etc.)

h. Immunologic disorders

i. Hormonal or endocrine disorders

j. Psychiatric illness that would interfere with his or her ability to comply with study procedures or that requires daily treatment with medication

k. Seizure disorder, with the exception of childhood febrile seizures

l. Malignancy, or

m. Any other condition that may interfere with the interpretation of the study results, or not be in the best interest of the subject in the opinion of the investigator

4. Fasting total cholesterol >240 mg/dL or fasting triglycerides >240 mg/dL on 2 consecutive visits

5. Fasting glucose >125 mg/dL on 2 consecutive visits

6. Current participation in an onging investigational drug protocol or use of any investigational drug within 30 days (based on last dose received) prior to receipt of any study drugs/medications.

7. Therapy with any prescription, over-the-counter, herbal, or holistic medications, including hormonal contraceptives by any route, within 5 half-lives of the agent prior to receipt of any study medications will not be permitted with the following exception: Intermittent or short-course therapy (< 14 days) with prescription or over-the-counter medications, herbals, or holistic medications within the screening period prior to starting study drug may be permitted, and will be reviewed by investigators on a case-by-case basis for potential drug interactions. Receipt of influenza vaccination will be allowed prior to, during, and/or after the study

8. Inability to obtain venous access for sample collection

9. Inability to swallow whole capsules and/or tablets

10. Current breastfeeding

11. Drug or alcohol use that may impair safety or adherence

12. Use of nicotine-containing products, including cigarettes and chewing tobacco, nicotine patches, gum, electronic cigarettes, etc.

13. Organ or stem cell transplant recipient

14. Uncorrected and persistent electrolyte abnormalities (e.g., potassium, magnesium, and calcium)

15. Current alcohol abuse or alcohol dependence disorders (DSM-5 criteria)

--Back to Top--


Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011 Jul 7;365(1):11-20. doi: 10.1056/NEJMoa1005136.

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Joseph A. Kovacs, M.D.
National Institutes of Health Clinical Center (CC)
(301) 496-9907

Doris Z. Swaim, R.N.
National Institutes of Health Clinical Center (CC)
National Institutes of Health
Building 10
Room 2C145
10 Center Drive
Bethesda, Maryland 20892
(301) 827-9716

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: TTY Users Dial 7-1-1

Clinical Trials Number:


--Back to Top--